Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.71 |
| ▸ | TK1 | P04183 | 6/20 | 0.57 |
| ▸ | TK2 | O00142 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334032 | 1.00 | RNASE1 (0.71) | RNASE1TK1TK2LMNATSHR | |
| SCHEMBL16704351 | 1.00 | RNASE1 (0.71) | RNASE1TK1TK2LMNATSHR | |
| SCHEMBL25752670 | 0.91 | RNASE1 (0.59) | RNASE1TK1TK2 | |
| SCHEMBL7922857 | 0.90 | RNASE1 (0.58) | RNASE1TK1TK2 | |
| SCHEMBL7922859 | 0.90 | RNASE1 (0.58) | RNASE1TK1TK2 | |
| SCHEMBL16704357 | 0.88 | RNASE1 (0.56) | RNASE1TK1TK2LMNATSHR | |
| SCHEMBL16704350 | 0.87 | RNASE1 (0.55) | RNASE1TK1TK2 | |
| SCHEMBL3912309 | 0.84 | RNASE1 (0.54) | RNASE1TK1TK2 | |
| SCHEMBL4578740 | 0.84 | TOP2A (0.58) | RNASE1TK1TK2 | |
| SCHEMBL29760775 | 0.84 | TOP2A (0.58) | RNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214382-A1 | Method for Preparing 3'-O-Amino-2'-Deoxyribonucleoside-5'-Triphosphate | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-07-15 | — | — | US | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
| US-8034923-B1 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT | 2011-10-11 | — | — | US | disclosed |
| WO-2010110775-A1 | REAGENTS FOR REVERSIBLY TERMINATING PRIMER EXTENSION | BENNER STEVEN ALBERT (US) | 2010-09-30 | — | — | WO | disclosed |
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-5969118-A | NUCLEOSIDES AND OLIGONUCLEOTIDES WITH INCREASED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5792844-A | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5618704-A | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | ISIS PHARMACUETICALS, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | RNASE1 135/4885TK1 76/4885TK2 98/4885 |
| US-20210214382-A1 | Method for Preparing 3'-O-Amino-2'-Deoxyribonucleoside-5'-Triphosphate | NUDT1, TYMP, NT5C3B | RNASE1 965/4885TK1 73/4885TK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.